

Global Drugs for Neuromyelitis Optica Market Growth 2023-2029

<https://marketpublishers.com/r/GE45E92D82D1EN.html>

Date: March 2023

Pages: 107

Price: US\$ 3,660.00 (Single User License)

ID: GE45E92D82D1EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.

Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.

LPI (LP Information)' newest research report, the “Drugs for Neuromyelitis Optica Industry Forecast” looks at past sales and reviews total world Drugs for Neuromyelitis Optica sales in 2022, providing a comprehensive analysis by region and market sector of projected Drugs for Neuromyelitis Optica sales for 2023 through 2029. With Drugs for Neuromyelitis Optica sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Drugs for Neuromyelitis Optica industry.

This Insight Report provides a comprehensive analysis of the global Drugs for

Neuromyelitis Optica landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Drugs for Neuromyelitis Optica portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Drugs for Neuromyelitis Optica market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Drugs for Neuromyelitis Optica and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Drugs for Neuromyelitis Optica.

The global Drugs for Neuromyelitis Optica market size is projected to grow from US\$ 46 million in 2022 to US\$ 59 million in 2029; it is expected to grow at a CAGR of 59 from 2023 to 2029.

Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.

The key players are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP etc. Top 3 companies occupied about 35% market share.

This report presents a comprehensive overview, market shares, and growth opportunities of Drugs for Neuromyelitis Optica market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

Glucocorticoids

Immunotherapies

Other

Segmentation by application

Acute Attack

Remission Prophylactic Treatment

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Pfizer

Fresenius

Teva

Sandoz

Intas

Gyjtrs

NANG KUANG

Tianjin Kingyork

Baxter

CSL

Grifols

Octapharma

CBOP

Key Questions Addressed in this Report

What is the 10-year outlook for the global Drugs for Neuromyelitis Optica market?

What factors are driving Drugs for Neuromyelitis Optica market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Drugs for Neuromyelitis Optica market opportunities vary by end market size?

How does Drugs for Neuromyelitis Optica break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Drugs for Neuromyelitis Optica Annual Sales 2018-2029
- 2.1.2 World Current & Future Analysis for Drugs for Neuromyelitis Optica by Geographic Region, 2018, 2022 & 2029
- 2.1.3 World Current & Future Analysis for Drugs for Neuromyelitis Optica by Country/Region, 2018, 2022 & 2029

2.2 Drugs for Neuromyelitis Optica Segment by Type

- 2.2.1 Glucocorticoids
- 2.2.2 Immunotherapies
- 2.2.3 Other

2.3 Drugs for Neuromyelitis Optica Sales by Type

- 2.3.1 Global Drugs for Neuromyelitis Optica Sales Market Share by Type (2018-2023)
- 2.3.2 Global Drugs for Neuromyelitis Optica Revenue and Market Share by Type (2018-2023)
- 2.3.3 Global Drugs for Neuromyelitis Optica Sale Price by Type (2018-2023)

2.4 Drugs for Neuromyelitis Optica Segment by Application

- 2.4.1 Acute Attack
- 2.4.2 Remission Prophylactic Treatment

2.5 Drugs for Neuromyelitis Optica Sales by Application

- 2.5.1 Global Drugs for Neuromyelitis Optica Sale Market Share by Application (2018-2023)
- 2.5.2 Global Drugs for Neuromyelitis Optica Revenue and Market Share by Application (2018-2023)
- 2.5.3 Global Drugs for Neuromyelitis Optica Sale Price by Application (2018-2023)

3 GLOBAL DRUGS FOR NEUROMYELITIS OPTICA BY COMPANY

3.1 Global Drugs for Neuromyelitis Optica Breakdown Data by Company

3.1.1 Global Drugs for Neuromyelitis Optica Annual Sales by Company (2018-2023)

3.1.2 Global Drugs for Neuromyelitis Optica Sales Market Share by Company (2018-2023)

3.2 Global Drugs for Neuromyelitis Optica Annual Revenue by Company (2018-2023)

3.2.1 Global Drugs for Neuromyelitis Optica Revenue by Company (2018-2023)

3.2.2 Global Drugs for Neuromyelitis Optica Revenue Market Share by Company (2018-2023)

3.3 Global Drugs for Neuromyelitis Optica Sale Price by Company

3.4 Key Manufacturers Drugs for Neuromyelitis Optica Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Drugs for Neuromyelitis Optica Product Location Distribution

3.4.2 Players Drugs for Neuromyelitis Optica Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR DRUGS FOR NEUROMYELITIS OPTICA BY GEOGRAPHIC REGION

4.1 World Historic Drugs for Neuromyelitis Optica Market Size by Geographic Region (2018-2023)

4.1.1 Global Drugs for Neuromyelitis Optica Annual Sales by Geographic Region (2018-2023)

4.1.2 Global Drugs for Neuromyelitis Optica Annual Revenue by Geographic Region (2018-2023)

4.2 World Historic Drugs for Neuromyelitis Optica Market Size by Country/Region (2018-2023)

4.2.1 Global Drugs for Neuromyelitis Optica Annual Sales by Country/Region (2018-2023)

4.2.2 Global Drugs for Neuromyelitis Optica Annual Revenue by Country/Region (2018-2023)

4.3 Americas Drugs for Neuromyelitis Optica Sales Growth

4.4 APAC Drugs for Neuromyelitis Optica Sales Growth

4.5 Europe Drugs for Neuromyelitis Optica Sales Growth

4.6 Middle East & Africa Drugs for Neuromyelitis Optica Sales Growth

5 AMERICAS

5.1 Americas Drugs for Neuromyelitis Optica Sales by Country

5.1.1 Americas Drugs for Neuromyelitis Optica Sales by Country (2018-2023)

5.1.2 Americas Drugs for Neuromyelitis Optica Revenue by Country (2018-2023)

5.2 Americas Drugs for Neuromyelitis Optica Sales by Type

5.3 Americas Drugs for Neuromyelitis Optica Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Drugs for Neuromyelitis Optica Sales by Region

6.1.1 APAC Drugs for Neuromyelitis Optica Sales by Region (2018-2023)

6.1.2 APAC Drugs for Neuromyelitis Optica Revenue by Region (2018-2023)

6.2 APAC Drugs for Neuromyelitis Optica Sales by Type

6.3 APAC Drugs for Neuromyelitis Optica Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Drugs for Neuromyelitis Optica by Country

7.1.1 Europe Drugs for Neuromyelitis Optica Sales by Country (2018-2023)

7.1.2 Europe Drugs for Neuromyelitis Optica Revenue by Country (2018-2023)

7.2 Europe Drugs for Neuromyelitis Optica Sales by Type

7.3 Europe Drugs for Neuromyelitis Optica Sales by Application

7.4 Germany

7.5 France

- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Drugs for Neuromyelitis Optica by Country
 - 8.1.1 Middle East & Africa Drugs for Neuromyelitis Optica Sales by Country (2018-2023)
 - 8.1.2 Middle East & Africa Drugs for Neuromyelitis Optica Revenue by Country (2018-2023)
- 8.2 Middle East & Africa Drugs for Neuromyelitis Optica Sales by Type
- 8.3 Middle East & Africa Drugs for Neuromyelitis Optica Sales by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Drugs for Neuromyelitis Optica
- 10.3 Manufacturing Process Analysis of Drugs for Neuromyelitis Optica
- 10.4 Industry Chain Structure of Drugs for Neuromyelitis Optica

11 MARKETING, DISTRIBUTORS AND CUSTOMER

- 11.1 Sales Channel
 - 11.1.1 Direct Channels
 - 11.1.2 Indirect Channels
- 11.2 Drugs for Neuromyelitis Optica Distributors
- 11.3 Drugs for Neuromyelitis Optica Customer

12 WORLD FORECAST REVIEW FOR DRUGS FOR NEUROMYELITIS OPTICA BY GEOGRAPHIC REGION

- 12.1 Global Drugs for Neuromyelitis Optica Market Size Forecast by Region
 - 12.1.1 Global Drugs for Neuromyelitis Optica Forecast by Region (2024-2029)
 - 12.1.2 Global Drugs for Neuromyelitis Optica Annual Revenue Forecast by Region (2024-2029)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Drugs for Neuromyelitis Optica Forecast by Type
- 12.7 Global Drugs for Neuromyelitis Optica Forecast by Application

13 KEY PLAYERS ANALYSIS

- 13.1 Pfizer
 - 13.1.1 Pfizer Company Information
 - 13.1.2 Pfizer Drugs for Neuromyelitis Optica Product Portfolios and Specifications
 - 13.1.3 Pfizer Drugs for Neuromyelitis Optica Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.1.4 Pfizer Main Business Overview
 - 13.1.5 Pfizer Latest Developments
- 13.2 Fresenius
 - 13.2.1 Fresenius Company Information
 - 13.2.2 Fresenius Drugs for Neuromyelitis Optica Product Portfolios and Specifications
 - 13.2.3 Fresenius Drugs for Neuromyelitis Optica Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.2.4 Fresenius Main Business Overview
 - 13.2.5 Fresenius Latest Developments
- 13.3 Teva
 - 13.3.1 Teva Company Information
 - 13.3.2 Teva Drugs for Neuromyelitis Optica Product Portfolios and Specifications
 - 13.3.3 Teva Drugs for Neuromyelitis Optica Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.3.4 Teva Main Business Overview
 - 13.3.5 Teva Latest Developments
- 13.4 Sandoz

- 13.4.1 Sandoz Company Information
- 13.4.2 Sandoz Drugs for Neuromyelitis Optica Product Portfolios and Specifications
- 13.4.3 Sandoz Drugs for Neuromyelitis Optica Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.4.4 Sandoz Main Business Overview
- 13.4.5 Sandoz Latest Developments
- 13.5 Intas
 - 13.5.1 Intas Company Information
 - 13.5.2 Intas Drugs for Neuromyelitis Optica Product Portfolios and Specifications
 - 13.5.3 Intas Drugs for Neuromyelitis Optica Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.5.4 Intas Main Business Overview
 - 13.5.5 Intas Latest Developments
- 13.6 Gyjtrs
 - 13.6.1 Gyjtrs Company Information
 - 13.6.2 Gyjtrs Drugs for Neuromyelitis Optica Product Portfolios and Specifications
 - 13.6.3 Gyjtrs Drugs for Neuromyelitis Optica Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.6.4 Gyjtrs Main Business Overview
 - 13.6.5 Gyjtrs Latest Developments
- 13.7 NANG KUANG
 - 13.7.1 NANG KUANG Company Information
 - 13.7.2 NANG KUANG Drugs for Neuromyelitis Optica Product Portfolios and Specifications
 - 13.7.3 NANG KUANG Drugs for Neuromyelitis Optica Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.7.4 NANG KUANG Main Business Overview
 - 13.7.5 NANG KUANG Latest Developments
- 13.8 Tianjin Kingyork
 - 13.8.1 Tianjin Kingyork Company Information
 - 13.8.2 Tianjin Kingyork Drugs for Neuromyelitis Optica Product Portfolios and Specifications
 - 13.8.3 Tianjin Kingyork Drugs for Neuromyelitis Optica Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.8.4 Tianjin Kingyork Main Business Overview
 - 13.8.5 Tianjin Kingyork Latest Developments
- 13.9 Baxter
 - 13.9.1 Baxter Company Information
 - 13.9.2 Baxter Drugs for Neuromyelitis Optica Product Portfolios and Specifications

13.9.3 Baxter Drugs for Neuromyelitis Optica Sales, Revenue, Price and Gross Margin (2018-2023)

13.9.4 Baxter Main Business Overview

13.9.5 Baxter Latest Developments

13.10 CSL

13.10.1 CSL Company Information

13.10.2 CSL Drugs for Neuromyelitis Optica Product Portfolios and Specifications

13.10.3 CSL Drugs for Neuromyelitis Optica Sales, Revenue, Price and Gross Margin (2018-2023)

13.10.4 CSL Main Business Overview

13.10.5 CSL Latest Developments

13.11 Grifols

13.11.1 Grifols Company Information

13.11.2 Grifols Drugs for Neuromyelitis Optica Product Portfolios and Specifications

13.11.3 Grifols Drugs for Neuromyelitis Optica Sales, Revenue, Price and Gross Margin (2018-2023)

13.11.4 Grifols Main Business Overview

13.11.5 Grifols Latest Developments

13.12 Octapharma

13.12.1 Octapharma Company Information

13.12.2 Octapharma Drugs for Neuromyelitis Optica Product Portfolios and Specifications

13.12.3 Octapharma Drugs for Neuromyelitis Optica Sales, Revenue, Price and Gross Margin (2018-2023)

13.12.4 Octapharma Main Business Overview

13.12.5 Octapharma Latest Developments

13.13 CBOP

13.13.1 CBOP Company Information

13.13.2 CBOP Drugs for Neuromyelitis Optica Product Portfolios and Specifications

13.13.3 CBOP Drugs for Neuromyelitis Optica Sales, Revenue, Price and Gross Margin (2018-2023)

13.13.4 CBOP Main Business Overview

13.13.5 CBOP Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Drugs for Neuromyelitis Optica Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)

Table 2. Drugs for Neuromyelitis Optica Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)

Table 3. Major Players of Glucocorticoids

Table 4. Major Players of Immunotherapies

Table 5. Major Players of Other

Table 6. Global Drugs for Neuromyelitis Optica Sales by Type (2018-2023) & (K Units)

Table 7. Global Drugs for Neuromyelitis Optica Sales Market Share by Type (2018-2023)

Table 8. Global Drugs for Neuromyelitis Optica Revenue by Type (2018-2023) & (\$ million)

Table 9. Global Drugs for Neuromyelitis Optica Revenue Market Share by Type (2018-2023)

Table 10. Global Drugs for Neuromyelitis Optica Sale Price by Type (2018-2023) & (US\$/Unit)

Table 11. Global Drugs for Neuromyelitis Optica Sales by Application (2018-2023) & (K Units)

Table 12. Global Drugs for Neuromyelitis Optica Sales Market Share by Application (2018-2023)

Table 13. Global Drugs for Neuromyelitis Optica Revenue by Application (2018-2023)

Table 14. Global Drugs for Neuromyelitis Optica Revenue Market Share by Application (2018-2023)

Table 15. Global Drugs for Neuromyelitis Optica Sale Price by Application (2018-2023) & (US\$/Unit)

Table 16. Global Drugs for Neuromyelitis Optica Sales by Company (2018-2023) & (K Units)

Table 17. Global Drugs for Neuromyelitis Optica Sales Market Share by Company (2018-2023)

Table 18. Global Drugs for Neuromyelitis Optica Revenue by Company (2018-2023) (\$ Millions)

Table 19. Global Drugs for Neuromyelitis Optica Revenue Market Share by Company (2018-2023)

Table 20. Global Drugs for Neuromyelitis Optica Sale Price by Company (2018-2023) & (US\$/Unit)

- Table 21. Key Manufacturers Drugs for Neuromyelitis Optica Producing Area Distribution and Sales Area
- Table 22. Players Drugs for Neuromyelitis Optica Products Offered
- Table 23. Drugs for Neuromyelitis Optica Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
- Table 24. New Products and Potential Entrants
- Table 25. Mergers & Acquisitions, Expansion
- Table 26. Global Drugs for Neuromyelitis Optica Sales by Geographic Region (2018-2023) & (K Units)
- Table 27. Global Drugs for Neuromyelitis Optica Sales Market Share Geographic Region (2018-2023)
- Table 28. Global Drugs for Neuromyelitis Optica Revenue by Geographic Region (2018-2023) & (\$ millions)
- Table 29. Global Drugs for Neuromyelitis Optica Revenue Market Share by Geographic Region (2018-2023)
- Table 30. Global Drugs for Neuromyelitis Optica Sales by Country/Region (2018-2023) & (K Units)
- Table 31. Global Drugs for Neuromyelitis Optica Sales Market Share by Country/Region (2018-2023)
- Table 32. Global Drugs for Neuromyelitis Optica Revenue by Country/Region (2018-2023) & (\$ millions)
- Table 33. Global Drugs for Neuromyelitis Optica Revenue Market Share by Country/Region (2018-2023)
- Table 34. Americas Drugs for Neuromyelitis Optica Sales by Country (2018-2023) & (K Units)
- Table 35. Americas Drugs for Neuromyelitis Optica Sales Market Share by Country (2018-2023)
- Table 36. Americas Drugs for Neuromyelitis Optica Revenue by Country (2018-2023) & (\$ Millions)
- Table 37. Americas Drugs for Neuromyelitis Optica Revenue Market Share by Country (2018-2023)
- Table 38. Americas Drugs for Neuromyelitis Optica Sales by Type (2018-2023) & (K Units)
- Table 39. Americas Drugs for Neuromyelitis Optica Sales by Application (2018-2023) & (K Units)
- Table 40. APAC Drugs for Neuromyelitis Optica Sales by Region (2018-2023) & (K Units)
- Table 41. APAC Drugs for Neuromyelitis Optica Sales Market Share by Region (2018-2023)

Table 42. APAC Drugs for Neuromyelitis Optica Revenue by Region (2018-2023) & (\$ Millions)

Table 43. APAC Drugs for Neuromyelitis Optica Revenue Market Share by Region (2018-2023)

Table 44. APAC Drugs for Neuromyelitis Optica Sales by Type (2018-2023) & (K Units)

Table 45. APAC Drugs for Neuromyelitis Optica Sales by Application (2018-2023) & (K Units)

Table 46. Europe Drugs for Neuromyelitis Optica Sales by Country (2018-2023) & (K Units)

Table 47. Europe Drugs for Neuromyelitis Optica Sales Market Share by Country (2018-2023)

Table 48. Europe Drugs for Neuromyelitis Optica Revenue by Country (2018-2023) & (\$ Millions)

Table 49. Europe Drugs for Neuromyelitis Optica Revenue Market Share by Country (2018-2023)

Table 50. Europe Drugs for Neuromyelitis Optica Sales by Type (2018-2023) & (K Units)

Table 51. Europe Drugs for Neuromyelitis Optica Sales by Application (2018-2023) & (K Units)

Table 52. Middle East & Africa Drugs for Neuromyelitis Optica Sales by Country (2018-2023) & (K Units)

Table 53. Middle East & Africa Drugs for Neuromyelitis Optica Sales Market Share by Country (2018-2023)

Table 54. Middle East & Africa Drugs for Neuromyelitis Optica Revenue by Country (2018-2023) & (\$ Millions)

Table 55. Middle East & Africa Drugs for Neuromyelitis Optica Revenue Market Share by Country (2018-2023)

Table 56. Middle East & Africa Drugs for Neuromyelitis Optica Sales by Type (2018-2023) & (K Units)

Table 57. Middle East & Africa Drugs for Neuromyelitis Optica Sales by Application (2018-2023) & (K Units)

Table 58. Key Market Drivers & Growth Opportunities of Drugs for Neuromyelitis Optica

Table 59. Key Market Challenges & Risks of Drugs for Neuromyelitis Optica

Table 60. Key Industry Trends of Drugs for Neuromyelitis Optica

Table 61. Drugs for Neuromyelitis Optica Raw Material

Table 62. Key Suppliers of Raw Materials

Table 63. Drugs for Neuromyelitis Optica Distributors List

Table 64. Drugs for Neuromyelitis Optica Customer List

Table 65. Global Drugs for Neuromyelitis Optica Sales Forecast by Region (2024-2029)

& (K Units)

Table 66. Global Drugs for Neuromyelitis Optica Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 67. Americas Drugs for Neuromyelitis Optica Sales Forecast by Country (2024-2029) & (K Units)

Table 68. Americas Drugs for Neuromyelitis Optica Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 69. APAC Drugs for Neuromyelitis Optica Sales Forecast by Region (2024-2029) & (K Units)

Table 70. APAC Drugs for Neuromyelitis Optica Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 71. Europe Drugs for Neuromyelitis Optica Sales Forecast by Country (2024-2029) & (K Units)

Table 72. Europe Drugs for Neuromyelitis Optica Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 73. Middle East & Africa Drugs for Neuromyelitis Optica Sales Forecast by Country (2024-2029) & (K Units)

Table 74. Middle East & Africa Drugs for Neuromyelitis Optica Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 75. Global Drugs for Neuromyelitis Optica Sales Forecast by Type (2024-2029) & (K Units)

Table 76. Global Drugs for Neuromyelitis Optica Revenue Forecast by Type (2024-2029) & (\$ Millions)

Table 77. Global Drugs for Neuromyelitis Optica Sales Forecast by Application (2024-2029) & (K Units)

Table 78. Global Drugs for Neuromyelitis Optica Revenue Forecast by Application (2024-2029) & (\$ Millions)

Table 79. Pfizer Basic Information, Drugs for Neuromyelitis Optica Manufacturing Base, Sales Area and Its Competitors

Table 80. Pfizer Drugs for Neuromyelitis Optica Product Portfolios and Specifications

Table 81. Pfizer Drugs for Neuromyelitis Optica Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 82. Pfizer Main Business

Table 83. Pfizer Latest Developments

Table 84. Fresenius Basic Information, Drugs for Neuromyelitis Optica Manufacturing Base, Sales Area and Its Competitors

Table 85. Fresenius Drugs for Neuromyelitis Optica Product Portfolios and Specifications

Table 86. Fresenius Drugs for Neuromyelitis Optica Sales (K Units), Revenue (\$

Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 87. Fresenius Main Business

Table 88. Fresenius Latest Developments

Table 89. Teva Basic Information, Drugs for Neuromyelitis Optica Manufacturing Base, Sales Area and Its Competitors

Table 90. Teva Drugs for Neuromyelitis Optica Product Portfolios and Specifications

Table 91. Teva Drugs for Neuromyelitis Optica Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 92. Teva Main Business

Table 93. Teva Latest Developments

Table 94. Sandoz Basic Information, Drugs for Neuromyelitis Optica Manufacturing Base, Sales Area and Its Competitors

Table 95. Sandoz Drugs for Neuromyelitis Optica Product Portfolios and Specifications

Table 96. Sandoz Drugs for Neuromyelitis Optica Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 97. Sandoz Main Business

Table 98. Sandoz Latest Developments

Table 99. Intas Basic Information, Drugs for Neuromyelitis Optica Manufacturing Base, Sales Area and Its Competitors

Table 100. Intas Drugs for Neuromyelitis Optica Product Portfolios and Specifications

Table 101. Intas Drugs for Neuromyelitis Optica Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 102. Intas Main Business

Table 103. Intas Latest Developments

Table 104. Gyjtrs Basic Information, Drugs for Neuromyelitis Optica Manufacturing Base, Sales Area and Its Competitors

Table 105. Gyjtrs Drugs for Neuromyelitis Optica Product Portfolios and Specifications

Table 106. Gyjtrs Drugs for Neuromyelitis Optica Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 107. Gyjtrs Main Business

Table 108. Gyjtrs Latest Developments

Table 109. NANG KUANG Basic Information, Drugs for Neuromyelitis Optica Manufacturing Base, Sales Area and Its Competitors

Table 110. NANG KUANG Drugs for Neuromyelitis Optica Product Portfolios and Specifications

Table 111. NANG KUANG Drugs for Neuromyelitis Optica Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 112. NANG KUANG Main Business

Table 113. NANG KUANG Latest Developments

- Table 114. Tianjin Kingyork Basic Information, Drugs for Neuromyelitis Optica Manufacturing Base, Sales Area and Its Competitors
- Table 115. Tianjin Kingyork Drugs for Neuromyelitis Optica Product Portfolios and Specifications
- Table 116. Tianjin Kingyork Drugs for Neuromyelitis Optica Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 117. Tianjin Kingyork Main Business
- Table 118. Tianjin Kingyork Latest Developments
- Table 119. Baxter Basic Information, Drugs for Neuromyelitis Optica Manufacturing Base, Sales Area and Its Competitors
- Table 120. Baxter Drugs for Neuromyelitis Optica Product Portfolios and Specifications
- Table 121. Baxter Drugs for Neuromyelitis Optica Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 122. Baxter Main Business
- Table 123. Baxter Latest Developments
- Table 124. CSL Basic Information, Drugs for Neuromyelitis Optica Manufacturing Base, Sales Area and Its Competitors
- Table 125. CSL Drugs for Neuromyelitis Optica Product Portfolios and Specifications
- Table 126. CSL Drugs for Neuromyelitis Optica Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 127. CSL Main Business
- Table 128. CSL Latest Developments
- Table 129. Grifols Basic Information, Drugs for Neuromyelitis Optica Manufacturing Base, Sales Area and Its Competitors
- Table 130. Grifols Drugs for Neuromyelitis Optica Product Portfolios and Specifications
- Table 131. Grifols Drugs for Neuromyelitis Optica Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 132. Grifols Main Business
- Table 133. Grifols Latest Developments
- Table 134. Octapharma Basic Information, Drugs for Neuromyelitis Optica Manufacturing Base, Sales Area and Its Competitors
- Table 135. Octapharma Drugs for Neuromyelitis Optica Product Portfolios and Specifications
- Table 136. Octapharma Drugs for Neuromyelitis Optica Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 137. Octapharma Main Business
- Table 138. Octapharma Latest Developments
- Table 139. CBOP Basic Information, Drugs for Neuromyelitis Optica Manufacturing Base, Sales Area and Its Competitors

Table 140. CBOP Drugs for Neuromyelitis Optica Product Portfolios and Specifications

Table 141. CBOP Drugs for Neuromyelitis Optica Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 142. CBOP Main Business

Table 143. CBOP Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Drugs for Neuromyelitis Optica
- Figure 2. Drugs for Neuromyelitis Optica Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Drugs for Neuromyelitis Optica Sales Growth Rate 2018-2029 (K Units)
- Figure 7. Global Drugs for Neuromyelitis Optica Revenue Growth Rate 2018-2029 (\$ Millions)
- Figure 8. Drugs for Neuromyelitis Optica Sales by Region (2018, 2022 & 2029) & (\$ Millions)
- Figure 9. Product Picture of Glucocorticoids
- Figure 10. Product Picture of Immunotherapies
- Figure 11. Product Picture of Other
- Figure 12. Global Drugs for Neuromyelitis Optica Sales Market Share by Type in 2022
- Figure 13. Global Drugs for Neuromyelitis Optica Revenue Market Share by Type (2018-2023)
- Figure 14. Drugs for Neuromyelitis Optica Consumed in Acute Attack
- Figure 15. Global Drugs for Neuromyelitis Optica Market: Acute Attack (2018-2023) & (K Units)
- Figure 16. Drugs for Neuromyelitis Optica Consumed in Remission Prophylactic Treatment
- Figure 17. Global Drugs for Neuromyelitis Optica Market: Remission Prophylactic Treatment (2018-2023) & (K Units)
- Figure 18. Global Drugs for Neuromyelitis Optica Sales Market Share by Application (2022)
- Figure 19. Global Drugs for Neuromyelitis Optica Revenue Market Share by Application in 2022
- Figure 20. Drugs for Neuromyelitis Optica Sales Market by Company in 2022 (K Units)
- Figure 21. Global Drugs for Neuromyelitis Optica Sales Market Share by Company in 2022
- Figure 22. Drugs for Neuromyelitis Optica Revenue Market by Company in 2022 (\$ Million)
- Figure 23. Global Drugs for Neuromyelitis Optica Revenue Market Share by Company in 2022
- Figure 24. Global Drugs for Neuromyelitis Optica Sales Market Share by Geographic

Region (2018-2023)

Figure 25. Global Drugs for Neuromyelitis Optica Revenue Market Share by Geographic Region in 2022

Figure 26. Americas Drugs for Neuromyelitis Optica Sales 2018-2023 (K Units)

Figure 27. Americas Drugs for Neuromyelitis Optica Revenue 2018-2023 (\$ Millions)

Figure 28. APAC Drugs for Neuromyelitis Optica Sales 2018-2023 (K Units)

Figure 29. APAC Drugs for Neuromyelitis Optica Revenue 2018-2023 (\$ Millions)

Figure 30. Europe Drugs for Neuromyelitis Optica Sales 2018-2023 (K Units)

Figure 31. Europe Drugs for Neuromyelitis Optica Revenue 2018-2023 (\$ Millions)

Figure 32. Middle East & Africa Drugs for Neuromyelitis Optica Sales 2018-2023 (K Units)

Figure 33. Middle East & Africa Drugs for Neuromyelitis Optica Revenue 2018-2023 (\$ Millions)

Figure 34. Americas Drugs for Neuromyelitis Optica Sales Market Share by Country in 2022

Figure 35. Americas Drugs for Neuromyelitis Optica Revenue Market Share by Country in 2022

Figure 36. Americas Drugs for Neuromyelitis Optica Sales Market Share by Type (2018-2023)

Figure 37. Americas Drugs for Neuromyelitis Optica Sales Market Share by Application (2018-2023)

Figure 38. United States Drugs for Neuromyelitis Optica Revenue Growth 2018-2023 (\$ Millions)

Figure 39. Canada Drugs for Neuromyelitis Optica Revenue Growth 2018-2023 (\$ Millions)

Figure 40. Mexico Drugs for Neuromyelitis Optica Revenue Growth 2018-2023 (\$ Millions)

Figure 41. Brazil Drugs for Neuromyelitis Optica Revenue Growth 2018-2023 (\$ Millions)

Figure 42. APAC Drugs for Neuromyelitis Optica Sales Market Share by Region in 2022

Figure 43. APAC Drugs for Neuromyelitis Optica Revenue Market Share by Regions in 2022

Figure 44. APAC Drugs for Neuromyelitis Optica Sales Market Share by Type (2018-2023)

Figure 45. APAC Drugs for Neuromyelitis Optica Sales Market Share by Application (2018-2023)

Figure 46. China Drugs for Neuromyelitis Optica Revenue Growth 2018-2023 (\$ Millions)

Figure 47. Japan Drugs for Neuromyelitis Optica Revenue Growth 2018-2023 (\$

Millions)

Figure 48. South Korea Drugs for Neuromyelitis Optica Revenue Growth 2018-2023 (\$ Millions)

Figure 49. Southeast Asia Drugs for Neuromyelitis Optica Revenue Growth 2018-2023 (\$ Millions)

Figure 50. India Drugs for Neuromyelitis Optica Revenue Growth 2018-2023 (\$ Millions)

Figure 51. Australia Drugs for Neuromyelitis Optica Revenue Growth 2018-2023 (\$ Millions)

Figure 52. China Taiwan Drugs for Neuromyelitis Optica Revenue Growth 2018-2023 (\$ Millions)

Figure 53. Europe Drugs for Neuromyelitis Optica Sales Market Share by Country in 2022

Figure 54. Europe Drugs for Neuromyelitis Optica Revenue Market Share by Country in 2022

Figure 55. Europe Drugs for Neuromyelitis Optica Sales Market Share by Type (2018-2023)

Figure 56. Europe Drugs for Neuromyelitis Optica Sales Market Share by Application (2018-2023)

Figure 57. Germany Drugs for Neuromyelitis Optica Revenue Growth 2018-2023 (\$ Millions)

Figure 58. France Drugs for Neuromyelitis Optica Revenue Growth 2018-2023 (\$ Millions)

Figure 59. UK Drugs for Neuromyelitis Optica Revenue Growth 2018-2023 (\$ Millions)

Figure 60. Italy Drugs for Neuromyelitis Optica Revenue Growth 2018-2023 (\$ Millions)

Figure 61. Russia Drugs for Neuromyelitis Optica Revenue Growth 2018-2023 (\$ Millions)

Figure 62. Middle East & Africa Drugs for Neuromyelitis Optica Sales Market Share by Country in 2022

Figure 63. Middle East & Africa Drugs for Neuromyelitis Optica Revenue Market Share by Country in 2022

Figure 64. Middle East & Africa Drugs for Neuromyelitis Optica Sales Market Share by Type (2018-2023)

Figure 65. Middle East & Africa Drugs for Neuromyelitis Optica Sales Market Share by Application (2018-2023)

Figure 66. Egypt Drugs for Neuromyelitis Optica Revenue Growth 2018-2023 (\$ Millions)

Figure 67. South Africa Drugs for Neuromyelitis Optica Revenue Growth 2018-2023 (\$ Millions)

Figure 68. Israel Drugs for Neuromyelitis Optica Revenue Growth 2018-2023 (\$

Millions)

Figure 69. Turkey Drugs for Neuromyelitis Optica Revenue Growth 2018-2023 (\$

Millions)

Figure 70. GCC Country Drugs for Neuromyelitis Optica Revenue Growth 2018-2023 (\$

Millions)

Figure 71. Manufacturing Cost Structure Analysis of Drugs for Neuromyelitis Optica in 2022

Figure 72. Manufacturing Process Analysis of Drugs for Neuromyelitis Optica

Figure 73. Industry Chain Structure of Drugs for Neuromyelitis Optica

Figure 74. Channels of Distribution

Figure 75. Global Drugs for Neuromyelitis Optica Sales Market Forecast by Region (2024-2029)

Figure 76. Global Drugs for Neuromyelitis Optica Revenue Market Share Forecast by Region (2024-2029)

Figure 77. Global Drugs for Neuromyelitis Optica Sales Market Share Forecast by Type (2024-2029)

Figure 78. Global Drugs for Neuromyelitis Optica Revenue Market Share Forecast by Type (2024-2029)

Figure 79. Global Drugs for Neuromyelitis Optica Sales Market Share Forecast by Application (2024-2029)

Figure 80. Global Drugs for Neuromyelitis Optica Revenue Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Drugs for Neuromyelitis Optica Market Growth 2023-2029

Product link: <https://marketpublishers.com/r/GE45E92D82D1EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GE45E92D82D1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970